Israel's Teva Q1 revenue and adjusted EPS beat estimates

Teva Pharmaceutical Industries..

29/04/2026 12:07

Overview

Israel pharmaceutical firm's Q1 revenue rose 2% yr/yr, beating analyst expectations

Adjusted EPS for Q1 beat analyst expectations

Company plans share repurchase program, subject to board approval and market conditions

Outlook

Teva maintains 2026 revenue outlook at $16.4-$16.8 bln, updated for Emalex transaction

Company expects 2026 non-GAAP diluted EPS of $1.91-$2.11, including Emalex impact

Teva preparing for potential Q4 2026 launch of olanzapine LAI, pending regulatory approval

Result Drivers

INNOVATIVE PRODUCT GROWTH - Higher revenues from key innovative brands, especially AUSTEDO, AJOVY, and UZEDY, drove results

GENERIC REVENUE DECLINE - Lower U.S. generics sales, mainly lenalidomide, due to increased competition weighed on results

CURRENCY IMPACT - Exchange rate movements, including hedging, boosted reported revenue and operating income

Company press release: ID:nGNE1ZkwQz

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$3.98 bln
$3.81 bln (3 Analysts)
Q1 Adjusted EPS
Beat
$0.53
$0.48 (3 Analysts)
Q1 Net Income
$369 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 12 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)